Natera publishes Signatera survival data in colorectal liver metastases study
Natera (NASDAQ:NTRA) announced publication of new clinical data in JAMA Oncology evaluating its Signatera molecular residual disease (MRD) test in patients with resected colorectal liver metastases (CRLM).







_1433712_640x360_2505698371509-640x360.webp&w=3840&q=75)
_1433714_640x360_2505692739905-640x360.webp&w=3840&q=75)


_1433696_640x360_2505697347531-640x360.webp&w=3840&q=75)